JP2018513388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513388A5 JP2018513388A5 JP2017555636A JP2017555636A JP2018513388A5 JP 2018513388 A5 JP2018513388 A5 JP 2018513388A5 JP 2017555636 A JP2017555636 A JP 2017555636A JP 2017555636 A JP2017555636 A JP 2017555636A JP 2018513388 A5 JP2018513388 A5 JP 2018513388A5
- Authority
- JP
- Japan
- Prior art keywords
- reg
- mscs
- patient
- cells
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 37
- 238000002560 therapeutic procedure Methods 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 30
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 208000027866 inflammatory disease Diseases 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 18
- 210000001616 monocyte Anatomy 0.000 claims description 16
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 230000002062 proliferating effect Effects 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 229960004641 rituximab Drugs 0.000 claims description 8
- 230000006052 T cell proliferation Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 229960003697 abatacept Drugs 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 229960004238 anakinra Drugs 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 229940090100 cimzia Drugs 0.000 claims description 2
- 229940073621 enbrel Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 229940048921 humira Drugs 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229940035567 orencia Drugs 0.000 claims description 2
- 229940116176 remicade Drugs 0.000 claims description 2
- 229940068638 simponi Drugs 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382206 | 2015-04-24 | ||
| EP15382206.9 | 2015-04-24 | ||
| PCT/EP2016/059196 WO2016170187A2 (en) | 2015-04-24 | 2016-04-25 | Biomarkers for determining the clinical response to cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513388A JP2018513388A (ja) | 2018-05-24 |
| JP2018513388A5 true JP2018513388A5 (enExample) | 2019-05-30 |
| JP6811724B2 JP6811724B2 (ja) | 2021-01-13 |
Family
ID=53015749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555636A Active JP6811724B2 (ja) | 2015-04-24 | 2016-04-25 | 細胞療法に対する臨床応答を決定するためのバイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10746729B2 (enExample) |
| EP (1) | EP3286562B1 (enExample) |
| JP (1) | JP6811724B2 (enExample) |
| CA (1) | CA2983950A1 (enExample) |
| HK (1) | HK1250176A1 (enExample) |
| IL (1) | IL255243B (enExample) |
| WO (1) | WO2016170187A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7343091B2 (ja) * | 2018-06-05 | 2023-09-12 | メディポスト・カンパニー・リミテッド | 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物 |
| WO2020009648A1 (en) * | 2018-07-02 | 2020-01-09 | Nextcell Pharma Ab | Msc prediction algorithm |
| CN113544261B (zh) * | 2019-02-27 | 2024-10-01 | 武田药品工业株式会社 | 用于同种异体疗法的改良的干细胞群 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| EP2298861B1 (en) * | 2004-03-22 | 2017-09-13 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
| JP5539886B2 (ja) * | 2007-10-17 | 2014-07-02 | ティクセル | Ｔｒ１細胞、間葉系幹細胞およびその使用 |
| US20140219921A1 (en) * | 2012-12-21 | 2014-08-07 | Rutgers, The State University Of New Jersey | Immunomodulating compositions and methods |
| AU2014230014B2 (en) * | 2013-03-15 | 2019-11-14 | Tigenix, S.A.U. | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC) |
| JP6412933B2 (ja) * | 2013-06-25 | 2018-10-24 | ティジェニクス エス．エー．ユー． | 免疫調節活性を有する細胞集団、その調製方法および使用 |
-
2016
- 2016-04-25 WO PCT/EP2016/059196 patent/WO2016170187A2/en not_active Ceased
- 2016-04-25 EP EP16722548.1A patent/EP3286562B1/en active Active
- 2016-04-25 HK HK18109614.7A patent/HK1250176A1/zh unknown
- 2016-04-25 US US15/568,563 patent/US10746729B2/en active Active
- 2016-04-25 JP JP2017555636A patent/JP6811724B2/ja active Active
- 2016-04-25 CA CA2983950A patent/CA2983950A1/en active Pending
-
2017
- 2017-10-24 IL IL255243A patent/IL255243B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lurier et al. | Transcriptome analysis of IL-10-stimulated (M2c) macrophages by next-generation sequencing | |
| Havenar-Daughton et al. | Cytokine-independent detection of antigen-specific germinal center T follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique | |
| Aschenbrenner et al. | An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells | |
| Moreau et al. | Effector mechanisms of rejection | |
| Reinhardt et al. | Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease | |
| Polimeno et al. | Regulatory T cells, interleukin (IL)‐6, IL‐8, V ascular endothelial growth factor (VEGF), CXC L10, CXC L11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma | |
| Zhou et al. | IL-34 regulates IL-6 and IL-8 production in human lung fibroblasts via MAPK, PI3K-Akt, JAK and NF-κB signaling pathways | |
| Galligan et al. | The role of circulating fibrocytes in inflammation and autoimmunity | |
| EP2460880B1 (en) | Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells | |
| Van Vugt et al. | Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts | |
| Márquez et al. | Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis | |
| Kim et al. | NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis | |
| Chemin et al. | EOMES‐positive CD4+ T cells are increased in PTPN22 (1858T) risk allele carriers | |
| Guan et al. | Interferon γ induced compositional changes in human bone marrow derived mesenchymal stem/stromal cells | |
| JP2013526845A (ja) | サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ | |
| US11262358B2 (en) | Infiltrating immune cell proportions predict anti-TNF response in colon biopsies | |
| FitzGerald et al. | emerging evidence for critical involvement of the interleukin‐17 pathway in both psoriasis and psoriatic arthritis | |
| Peng et al. | Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure | |
| JP2018513388A5 (enExample) | ||
| Delmas et al. | Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40 | |
| Zhong et al. | Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease | |
| Singh et al. | Analysis of CXCR5+ Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis | |
| Yin et al. | Circulating Tfh cell and subsets distribution are associated with low‐responsiveness to hepatitis B vaccination | |
| Rodriguez-Rodriguez et al. | Rheumatoid arthritis: genetic variants as biomarkers of cardiovascular disease | |
| Webb et al. | Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists |